Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
BRTX 
BioRestorative Therapies Inc (BRTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/07/2026: BRTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13
1 Year Target Price $13
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.57% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/07/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.47M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) 2 | Beta 0.18 | 52 Weeks Range 0.98 - 2.55 | Updated Date 01/7/2026 |
52 Weeks Range 0.98 - 2.55 | Updated Date 01/7/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.46 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -31432.3% |
Management Effectiveness
Return on Assets (TTM) -89.73% | Return on Equity (TTM) -207.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -2646262 | Price to Sales(TTM) 27.32 |
Enterprise Value -2646262 | Price to Sales(TTM) 27.32 | ||
Enterprise Value to Revenue 1.27 | Enterprise Value to EBITDA 0.13 | Shares Outstanding 8876242 | Shares Floating 5993949 |
Shares Outstanding 8876242 | Shares Floating 5993949 | ||
Percent Insiders 22.35 | Percent Institutions 9.37 |
Upturn AI SWOT
BioRestorative Therapies Inc
Company Overview
History and Background
BioRestorative Therapies Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing regenerative medicine products. Founded in 2004, the company has primarily concentrated on its proprietary cell therapy platform. A significant milestone was its focus on developing treatments for disc-related conditions and neurodegenerative diseases.
Core Business Areas
- ThermoStemu00ae Platform: The company's core technology revolves around its ThermoStemu00ae platform, which involves the use of autologous adipose-derived stem cells. These cells are processed and intended for therapeutic applications, primarily in spinal disc repair and potential treatments for conditions like Alzheimer's and Parkinson's disease.
Leadership and Structure
BioRestorative Therapies Inc. is led by a management team with experience in the biotechnology and pharmaceutical sectors. The organizational structure is typical of a clinical-stage company, with a focus on research and development, clinical trials, and regulatory affairs.
Top Products and Market Share
Key Offerings
- ThermoStemu00ae for Disc Disease: This is the company's lead product candidate, intended for the treatment of degenerative disc disease. It involves harvesting a patient's own fat tissue, isolating stem cells, and re-injecting them into the damaged intervertebral discs. The company aims to promote tissue regeneration and alleviate pain. Competitors in this space include companies developing surgical interventions, other cell-based therapies, and non-surgical pain management solutions.
- ThermoStemu00ae for Neurodegenerative Diseases: BioRestorative is also exploring the potential of ThermoStemu00ae for treating neurodegenerative conditions such as Alzheimer's and Parkinson's disease. This application is in earlier stages of development, focusing on the neuroprotective and regenerative properties of stem cells. Competitors include pharmaceutical companies developing drug therapies and other research institutions investigating cell-based treatments for these complex diseases.
Market Dynamics
Industry Overview
The regenerative medicine and cell therapy market is a rapidly growing sector within the broader biopharmaceutical industry. It is characterized by significant investment in research and development, a focus on addressing unmet medical needs, and a complex regulatory pathway.
Positioning
BioRestorative Therapies Inc. is positioned as a developer of autologous stem cell therapies. Its competitive advantage lies in its proprietary ThermoStemu00ae platform and its focus on specific, often underserved, therapeutic areas like degenerative disc disease and neurodegenerative disorders. However, as a clinical-stage company, it faces the challenges inherent in bringing novel therapies through rigorous clinical trials and regulatory approval.
Total Addressable Market (TAM)
The Total Addressable Market (TAM) for treatments of degenerative disc disease and neurodegenerative diseases is substantial, encompassing millions of patients globally. For degenerative disc disease alone, the market is valued in the billions of dollars. BioRestorative Therapies Inc. is positioned to capture a portion of this market if its ThermoStemu00ae therapy proves safe and effective and receives regulatory approval, but it faces competition from established and emerging therapies.
Upturn SWOT Analysis
Strengths
- Proprietary ThermoStemu00ae cell therapy platform.
- Focus on addressing significant unmet medical needs in pain management and neurodegenerative diseases.
- Autologous (patient's own cells) approach may reduce immune rejection concerns.
- Clinical-stage company with ongoing research and development activities.
Weaknesses
- Clinical-stage status, meaning no approved products to generate revenue.
- Reliance on successful completion of clinical trials and regulatory approvals.
- Limited financial resources compared to larger pharmaceutical companies.
- Potential challenges in scaling manufacturing for widespread commercialization.
- Competition from established and emerging treatments.
Opportunities
- Significant unmet needs in degenerative disc disease and neurodegenerative disorders.
- Growing interest and investment in regenerative medicine and cell therapies.
- Potential for partnerships or collaborations with larger pharmaceutical companies.
- Expansion of ThermoStemu00ae platform to other therapeutic areas.
Threats
- Failure to demonstrate efficacy or safety in clinical trials.
- Regulatory hurdles and lengthy approval processes.
- Intense competition from established and emerging therapies.
- Changes in healthcare reimbursement policies.
- Economic downturns impacting healthcare spending and investment.
Competitors and Market Share
Key Competitors
- Companies developing cell therapies for orthopedic conditions (e.g., disc repair).
- Biopharmaceutical companies with drug candidates for Alzheimer's and Parkinson's.
- Companies offering surgical or other non-cell-based interventions for degenerative disc disease.
Competitive Landscape
BioRestorative Therapies Inc. operates in a competitive landscape where larger, more established pharmaceutical companies and numerous smaller biotech firms are also developing treatments for similar conditions. The company's advantage lies in its specific autologous stem cell approach and targeted indications, but it faces significant challenges in navigating the complex clinical and regulatory pathways and competing for market share against well-funded entities.
Growth Trajectory and Initiatives
Historical Growth: Historically, BioRestorative Therapies Inc.'s growth has been characterized by progress in its research and development pipeline and the advancement of its ThermoStemu00ae platform through various stages of preclinical and clinical investigation. Growth is measured by scientific milestones rather than financial revenue growth.
Future Projections: Future growth projections for BioRestorative Therapies Inc. are contingent upon the successful completion of its clinical trials, securing regulatory approvals, and effective commercialization of its therapies. Analyst projections, if available, would be based on these key de-risking events. Significant growth is anticipated only upon product launch.
Recent Initiatives: Recent initiatives likely involve the progression of clinical trials for its lead indications, efforts to optimize manufacturing processes for its cell therapies, and potential strategic partnerships or collaborations to advance its pipeline.
Summary
BioRestorative Therapies Inc. is a clinical-stage company focused on regenerative medicine with its ThermoStemu00ae cell therapy platform. Its strengths lie in its proprietary technology and focus on significant unmet medical needs. However, it faces substantial risks due to its clinical-stage status, reliance on trial success, and intense competition. The company's future success hinges on navigating regulatory hurdles and demonstrating clinical efficacy and safety to secure market entry and generate revenue.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (e.g., SEC filings)
- Industry reports and market analysis
- Financial news and data providers
Disclaimers:
This JSON output provides a structured overview of BioRestorative Therapies Inc. based on publicly available information. It is intended for informational purposes only and does not constitute financial advice or an endorsement of the company. Investing in clinical-stage biopharmaceutical companies carries significant risk. All data is subject to change, and users should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioRestorative Therapies Inc
Exchange NASDAQ | Headquaters Melville, NY, United States | ||
IPO Launch date 2007-07-27 | Chairman of the Board, President & CEO Mr. Lance Alstodt | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11 | Website https://www.biorestorative.com |
Full time employees 11 | Website https://www.biorestorative.com | ||
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. It also operates a commercial biocosmeceutical platform. In addition, the company provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.